Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Laurus-Labs"

29 News Found

Laurus Labs posts Q4 FY24 consolidated PAT at Rs. 75.61 Cr
News | April 26, 2024

Laurus Labs posts Q4 FY24 consolidated PAT at Rs. 75.61 Cr

Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024


Laurus Labs forms JV company
News | April 16, 2024

Laurus Labs forms JV company

KRKA holds 51% and Laurus Labs holds 49% shareholding


Laurus Labs inks JV agreement with KRKA, Slovenia
News | January 26, 2024

Laurus Labs inks JV agreement with KRKA, Slovenia

The registered capital of the newly founded company is € 50 million


Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr
News | January 25, 2024

Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr

Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023


Laurus Labs acquires 87.59% stake in Laurus Bio Private
News | November 25, 2023

Laurus Labs acquires 87.59% stake in Laurus Bio Private

Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders


Laurus Labs Q2 FY24 consolidated PAT up QOQ at Rs. 36.95 Cr
News | October 21, 2023

Laurus Labs Q2 FY24 consolidated PAT up QOQ at Rs. 36.95 Cr

Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023


Laurus Labs posts decline in Q1FY24 consolidated PAT to Rs. 24.85 Cr
News | July 28, 2023

Laurus Labs posts decline in Q1FY24 consolidated PAT to Rs. 24.85 Cr

The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023


Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets
Biotech | June 19, 2023

Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets

Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets


Laurus Labs to increase stake in ImmunoACT to 33.86%
News | June 01, 2023

Laurus Labs to increase stake in ImmunoACT to 33.86%

This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19


Laurus Labs receives USFDA tentative approval for Dolutegravir 5mg and 10mg in HIV/AIDS treatment
Drug Approval | May 03, 2023

Laurus Labs receives USFDA tentative approval for Dolutegravir 5mg and 10mg in HIV/AIDS treatment

It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment